Report of the Australian and New Zealand combined dialysis and transplant registry

The Medical Journal of Australia
A P Disney, R L Correll


In Australia, 463 patients (32/1,000,000 population) commenced commercial treatment by dialysis in 1979. In all, 1266 dialysis patients (88/1,000,000) were receiving treatment at October 31, 1979, 47% by home dialysis. In 1979, 316 transplants (22/1,000,000) were performed. Of 1237 functioning grafts (86/1,000,000) at October 31, 1979, 89% were primary grafts; 6.5 of all functioning grafts were from a living donor. During 1979, the number of dialysis patients exceeded that of patients with a functioning transplant for the first time since the Registry was started. Amongst new patients, in 1979, glomerulonephritis (35%), analgesic nephropathy (19%), polycystic renal disease (9%), and reflux nephropathy (7%) were the more common primary renal diseases. Four per cent of patients had diabetic renal failure. The proportion of new patients over 50 years of age increased from 31% in 1973 to 46% in 1979; 14% were 60 years old or older in 1979. In 1975-1978, the three-year patient survival for integrated treatment (dialysis and/or transplantation) was 65%; the age-related patient survival at three years was approximately 80% for those under 40 years of age, 60% for those from 40 to 59 years of age, and 40% for patients over 60 years of ...Continue Reading


May 5, 1979·The Medical Journal of Australia·J F MahonyJ H Stewart
Nov 2, 1974·The Medical Journal of Australia·A P Disney, P G Row
Jan 1, 1955·Journal of Chronic Diseases·M MERRELL, L E SHULMAN

❮ Previous
Next ❯


Feb 1, 1986·Australian and New Zealand Journal of Medicine·P W CraswellG M Williams
Nov 1, 1983·Anaesthesia and Intensive Care·A R Marsland, J P Bradley
Jul 23, 1983·The Medical Journal of Australia·T H Mathew

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Schweizerische medizinische Wochenschrift
F P Brunner, G Thiel
Clinical Transplants
M Hirata, P I Terasaki
Clinical Transplants
H Koyama, J M Cecka
© 2021 Meta ULC. All rights reserved